https://doi.org/10.55788/1ca4759c
Dr Amara Sarwal (University of Utah Health, UT, USA) discussed the outcomes of a large meta-analysis of 4 trials examining the effects of blood pressure goals on CV outcomes. Over 15,000 patients were included with 1,614 CV events over 59,925 person-years of follow-up. “We observed that intensive blood pressure control [ed. treatment to a systolic blood-pressure target of 110-130 mm Hg] resulted in an overall lower hazard of CV events (HR 0.79; 95% CI 0.72–0.87). A lower baseline diastolic blood pressure was associated with an increased risk of CV events in 2 of the 4 studies,” Dr Sarwal added. “The interaction term of baseline diastolic blood pressure and the blood pressure intervention on CV events was non-significant in each of the studies and pooled overall. If lowering the systolic blood pressure in those with lower baseline diastolic blood pressure is harmful, the interaction term would be significant. The non-significance of the interaction terms means that there is no evidence that lowering systolic blood pressure in those with lower baseline diastolic blood pressure is harmful [1].”
- Sarwal A, et al. Influence of Baseline Diastolic BP (DBP) on the Effects of BP Lowering on Cardiovascular (CV) Outcomes: A Meta-Analysis of NIH BP Trials. TH-OR23, ASN Kidney Week 2022, 3–6 Nov.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« PROTECT trial: Pegloticase for Uncontrolled Gout in Kidney Transplant Recipients Next Article
Significantly higher risk of overcorrection in hyponatraemic patients with standard bolus infusion »
« PROTECT trial: Pegloticase for Uncontrolled Gout in Kidney Transplant Recipients Next Article
Significantly higher risk of overcorrection in hyponatraemic patients with standard bolus infusion »
Table of Contents: ASN 2022
Featured articles
Chronic Kidney Disease
VALOR-CKD trial did not show any benefits for veverimer
EMPA-KIDNEY: empagliflozin slashes kidney disease progression or CV death
Combining UACR and GFR improves prediction of drug effect in CKD phase 2 trials
Dapagliflozin reduces number of hospitalisations in patients with CKD
Novel MSC therapy appears safe and effective in preventing decline in eGFR
Dapagliflozin improves anaemia in patients with CKD with or without T2D
Kidney Transplantation and Dialysis
Balanced crystalloid solution better for deceased donor kidney transplantations
Modified donor blood cells seem a promising option in kidney transplant recipients
Cooler dialysate does not offer any clinical benefits
Antiviral effect of MAU868 against BK virus prompts further research
General Nephrology
Medication-targeted alerts for the risk of AKI
Coaching with a DASH diet improves albuminuria
Cemdisiran shows promise in IgA nephropathy
Long-term nephroprotective effects of sparsentan in FSGS
Encaleret normalises mineral homeostasis in patients with ADH1
Adding voclosporin to MMF and steroids results in long-term higher CRR in severe lupus nephritis
Selonsertib poses risk of AKI in patients with DKD
Significantly higher risk of overcorrection in hyponatraemic patients with standard bolus infusion
Lowering blood pressure intervention favourable for CV outcomes
Related Articles
February 26, 2024
Join the conversation on Rare Disease Awareness Day
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com